340 related articles for article (PubMed ID: 28074476)
1. Drug Development, Trial Design, and Endpoints in Oncology: Adapting to Rapidly Changing Science.
Blumenthal GM; Goldberg KB; Pazdur R
Clin Pharmacol Ther; 2017 May; 101(5):572-574. PubMed ID: 28074476
[TBL] [Abstract][Full Text] [Related]
2. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
3. Should the FDA be the doctor of last resort?
DeVita VT
Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
[No Abstract] [Full Text] [Related]
4. Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology.
Kern KA
J Oncol Pract; 2016 Aug; 12(8):e810-7. PubMed ID: 27460496
[TBL] [Abstract][Full Text] [Related]
5. Accelerated approval and oncology drug development timelines.
Lanthier ML; Sridhara R; Johnson JR; Farrell A; Keegan P; Justice R; Pazdur R
J Clin Oncol; 2010 May; 28(14):e226-7; author reply e228. PubMed ID: 20194846
[No Abstract] [Full Text] [Related]
6. Accelerated approval and breakthrough therapy designation: oncology drug development on speed?
Yao JC; Meric-Bernstam F; Lee JJ; Eckhardt SG
Clin Cancer Res; 2013 Aug; 19(16):4305-8. PubMed ID: 23833307
[TBL] [Abstract][Full Text] [Related]
7. The seamless approach to drug development in oncology.
Pazdur R
Clin Adv Hematol Oncol; 2016 Dec; 14(12):958-959. PubMed ID: 28212356
[No Abstract] [Full Text] [Related]
8. The ODAC chronicles--part 2. Statistics and clinical medicine in the USA: the triumph of science over art?
Grillo-López AJ
Expert Rev Anticancer Ther; 2004 Dec; 4(6):941-4. PubMed ID: 15606323
[No Abstract] [Full Text] [Related]
9. Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
[TBL] [Abstract][Full Text] [Related]
10. Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.
Theoret MR; Pai-Scherf LH; Chuk MK; Prowell TM; Balasubramaniam S; Kim T; Kim G; Kluetz PG; Keegan P; Pazdur R
Clin Cancer Res; 2015 Oct; 21(20):4545-51. PubMed ID: 26473190
[TBL] [Abstract][Full Text] [Related]
11. Response Rate as an Approval End Point in Oncology: Back to the Future.
Blumenthal GM; Pazdur R
JAMA Oncol; 2016 Jun; 2(6):780-1. PubMed ID: 26913938
[No Abstract] [Full Text] [Related]
12. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
[TBL] [Abstract][Full Text] [Related]
13. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
Yamashita K; Kaneko M; Narukawa M
Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731
[TBL] [Abstract][Full Text] [Related]
14. Rare cancer trial design: lessons from FDA approvals.
Gaddipati H; Liu K; Pariser A; Pazdur R
Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
[TBL] [Abstract][Full Text] [Related]
15. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
Kwok M; Foster T; Steinberg M
Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
Kesselheim AS; Myers JA; Avorn J
JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
[TBL] [Abstract][Full Text] [Related]
17. Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
Ben-Aharon O; Magnezi R; Leshno M; Goldstein DA
Oncologist; 2019 Nov; 24(11):1469-1478. PubMed ID: 31320502
[TBL] [Abstract][Full Text] [Related]
18. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.
Beaver JA; Howie LJ; Pelosof L; Kim T; Liu J; Goldberg KB; Sridhara R; Blumenthal GM; Farrell AT; Keegan P; Pazdur R; Kluetz PG
JAMA Oncol; 2018 Jun; 4(6):849-856. PubMed ID: 29494733
[TBL] [Abstract][Full Text] [Related]
19. A note on breast cancer trials with pCR-based accelerated approval.
Xia Y; Cui L; Yang B
J Biopharm Stat; 2014; 24(5):1102-14. PubMed ID: 24926729
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.
Bast RC; Thigpen JT; Arbuck SG; Basen-Engquist K; Burke LB; Freedman R; Horning SJ; Ozols R; Rustin GJ; Spriggs D; Wenzel LB; Pazdur R
Gynecol Oncol; 2007 Nov; 107(2):173-6. PubMed ID: 17950384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
